Metastatic melanoma cells evade immune detection by silencing STAT1

International Journal of Molecular Sciences

Volumn 16, Issue 2, 2015, Pages 4343-4361

  Osborn, Jodi Lynn ^a   Greer, Susanna F ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Immunosurveillance; Melanoma; MHC II; STAT1

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BETA ACTIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA INTERFERON RECEPTOR 1; HLA DR ANTIGEN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; JANUS KINASE 1; JANUS KINASE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NUCLEAR FACTOR Y; STAT1 PROTEIN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; HLA ANTIGEN CLASS 2; INTERFERON RECEPTOR; JANUS KINASE; TUMOR MARKER;

ARTICLE; CELL COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IMMUNE EVASION; IMMUNOFLUORESCENCE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; MELANOCYTE; MELANOMA CELL LINE; METASTATIC MELANOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIAL GROWTH PHASE; TISSUE MICROARRAY; TUMOR ESCAPE; TUMOR GROWTH; UPREGULATION; VERTICAL GROWTH PHASE; WESTERN BLOTTING; DRUG EFFECTS; GENE EXPRESSION; GENETICS; MELANOMA; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; JANUS KINASES; MELANOMA; MUTATION; PHOSPHORYLATION; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR;

EID: 84923105991     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16024343     Document Type: Article

References (63)

1. Clark, W.H., Jr.; Ainsworth, A.M.; Bernardino, E.A.; Yang, C.H.; Mihm, C.M., Jr.; Reed, R.J. The developmental biology of primary human malignant melanomas. Semin. Oncol. 1975, 2, 83–103.
2. Cichorek, M.; Wachulska, M.; Stasiewicz, A.; Tyminska, A. Skin melanocytes: Biology and development. Postepy Dermatol. Alergol. 2013, 30, 30–41.
3. Crutcher, W.A. Dysplastic Nevi—Markers and precursors of malignant melanoma. West. J. Med. 1987, 147, 459.
4. Ciarletta, P.; Foret, L.; Ben Amar, M. The radial growth phase of malignant melanoma: Multi-phase modelling, numerical simulations and linear stability analysis. J. R. Soc. Interface 2011, 8, 345–368.
5. Herlyn, M.; Thurin, J.; Balaban, G.; Bennicelli, J.L.; Herlyn, D.; Elder, D.E.; Bondi, E.; Guerry, D.; Nowell, P.; Clark, W.H.; et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 1985, 45, 5670–5676.
6. Laga, A.C.; Murphy, G.F. Cellular heterogeneity in vertical growth phase melanoma. Arch. Pathol. Lab. Med. 2010, 134, 1750–1757.
7. Rak, J.W.; Hegmann, E.J.; Lu, C.; Kerbel, R.S. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J. Cell. Physiol. 1994, 159, 245–255.
8. Liotta, L.A.; Guirguis, R.; Stracke, M. Biology of melanoma invasion and metastasis. Pigment Cell Res. 1987, 1, 5–15.
9. Mlecnik, B.; Bindea, G.; Pages, F.; Galon, J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 2011, 30, 5–12.
10. Srivastava, N.; McDermott, D. Update on benefit of immunotherapy and targeted therapy in melanoma: The changing landscape. Cancer Manag. Res. 2014, 6, 279–289.
11. Gajewski, T.F. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res. 2006, 12, 2326s–2330s.
12. Braciale, T.J.; Morrison, L.A.; Sweetser, M.T.; Sambrook, J.; Gething, M.J.; Braciale, V.L. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol. Rev. 1987, 98, 95–114.
13. Gerloni, M.; Zanetti, M. CD4 T cells in tumor immunity. Springer Semin. Immunopathol. 2005, 27, 37–48.
14. Garrido, F.; Cabrera, T.; Aptsiauri, N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. Int. J. Cancer 2010, 127, 249–256.
15. Matsushita, H.; Vesely, M.D.; Koboldt, D.C.; Rickert, C.G.; Uppaluri, R.; Magrini, V.J.; Arthur, C.D.; White, J.M.; Chen, Y.S.; Shea, L.K.; et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482, 400–404.
16. Nishimura, T.; Iwakabe, K.; Sekimoto, M.; Ohmi, Y.; Yahata, T.; Nakui, M.; Sato, T.; Habu, S.; Tashiro, H.; Sato, M.; et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 1999, 190, 617–627.
17. Gao, F.G.; Khammanivong, V.; Liu, W.J.; Leggatt, G.R.; Frazer, I.H.; Fernando, G.J. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res. 2002, 62, 6438–6441.
18. Antony, P.A.; Piccirillo, C.A.; Akpinarli, A.; Finkelstein, S.E.; Speiss, P.J.; Surman, D.R.; Palmer, D.C.; Chan, C.C.; Klebanoff, C.A.; Overwijk, W.W.; et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174, 2591–2601.
19. Janssen, E.M.; Lemmens, E.E.; Wolfe, T.; Christen, U.; von Herrath, M.G.; Schoenberger, S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421, 852–856.
20. Ostrand-Rosenberg, S.; Thakur, A.; Clements, V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 1990, 144, 4068–4071.
21. Ostrand-Rosenberg, S.; Roby, C.A.; Clements, V.K. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J. Immunol. 1991, 147, 2419–2422.
22. Muranski, P.; Boni, A.; Antony, P.A.; Cassard, L.; Irvine, K.R.; Kaiser, A.; Paulos, C.M.; Palmer, D.C.; Touloukian, C.E.; Ptak, K.; et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112, 362–373.
23. Corthay, A.; Lundin, K.U.; Lorvik, K.B.; Hofgaard, P.O.; Bogen, B. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res. 2009, 69, 5901–5907.
24. Xie, Y.; Akpinarli, A.; Maris, C.; Hipkiss, E.L.; Lane, M.; Kwon, E.K.; Muranski, P.; Restifo, N.P.; Antony, P.A. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 2010, 207, 651–667.
25. Haabeth, O.A.; Lorvik, K.B.; Hammarstrom, C.; Donaldson, I.M.; Haraldsen, G.; Bogen, B.; Corthay, A. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat. Commun. 2011, 2, 240.
26. Corthay, A.; Skovseth, D.K.; Lundin, K.U.; Rosjo, E.; Omholt, H.; Hofgaard, P.O.; Haraldsen, G.; Bogen, B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005, 22, 371–383.
27. Quezada, S.A.; Simpson, T.R.; Peggs, K.S.; Merghoub, T.; Vider, J.; Fan, X.; Blasberg, R.; Yagita, H.; Muranski, P.; Antony, P.A.; et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010, 207, 637–650.
28. Perez-Diez, A.; Joncker, N.T.; Choi, K.; Chan, W.F.; Anderson, C.C.; Lantz, O.; Matzinger, P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109, 5346–5354.
29. Fujiwara, H.; Fukuzawa, M.; Yoshioka, T.; Nakajima, H.; Hamaoka, T. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host’s cytotoxic T cell precursors for implementation of in vivo immunity. J. Immunol. 1984, 133, 1671-1676.
30. Greenberg, P.D.; Kern, D.E.; Cheever, M.A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+2-T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 1985, 161, 1122-1134.
31. Lauritzsen, G.F.; Weiss, S.; Dembic, Z.; Bogen, B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. USA 1994, 91, 5700-5704.
32. Rudensky, A.; Preston-Hurlburt, P.; Hong, S.C.; Barlow, A.; Janeway, CA., Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991, 353, 622-627.
33. Sartoris, S.; Scupoli, M.T.; Scarpellino, L.; Paiola, F.; Jotterand-Bellomo, M.; Tridente, G; Accolla, R.S. Inducible and constitutive MHC class II gene expression. Distinct tissue-specific genetic controls. J. Immunol. 1990, 145, 1960-1967.
34. Billiau, A.; Matthys, P. Interferon-y: A historical perspective. Cytokine Growth Factor Rev. 2009, 20, 97-113.
35. Schroder, K.; Hertzog, P.J.; Ravasi, T.; Hume, D.A. Interferon-y: An overview of signals, mechanisms and functions. J. Leukocyte Biol. 2004, 75, 163-189.
36. Igarashi, K.; Garotta, G; Ozmen, L.; Ziemiecki, A.; Wilks, A.F.; Harpur, A.G; Larner, A.C.; Finbloom, D.S. Interferon-y induces tyrosine phosphorylation of interferon-y receptor and regulated association of protein tyrosine kinases, JAK1 and JAK2, with its receptor. J. Biol. Chem. 1994, 269, 14333-14336.
37. Sakatsume, M.; Igarashi, K.; Winestock, K.D.; Garotta, G; Larner, A.C.; Finbloom, D.S. The JAK kinases differentially associate with the a and ß (accessory factor) chains of the interferon y receptor to form a functional receptor unit capable of activating STAT transcription factors. J. Biol. Chem. 1995, 270, 17528-17534.
38. Shuai, K.; Horvath, CM.; Huang, L.H.; Qureshi, S.A.; Cowburn, D.; Darnell, J.E., Jr. Interferon activation of the transcription factor STAT91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994, 76, 821-828.
39. Nguyen, H.; Hiscott, J.; Pitha, P.M. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 1997, 8, 293-312.
40. Masternak, K.; Muhlethaler-Mottet, A.; Villard, J.; Zufferey, M.; Steimle, V.; Reith, W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 2000, 14, 1156-1166.
41. Zika, E.; Greer, S.F.; Zhu, X.S.; Ting, J.P. Histone deacetylase 1/mSin3a disrupts γ interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol. Cell. Biol. 2003, 23, 3091-3102.
42. Spilianakis, C; Kretsovali, A.; Agalioti, T.; Makatounakis, T.; Thanos, D.; Papamatheakis, J. CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II. EMBO J. 2003, 22, 5125-5136.
43. Degenhardt, Y.; Huang, J.; Greshock, J.; Horiates, G.; Nathanson, K.; Yang, X.; Herlyn, M.; Weber, B. Distinct MHC gene expression patterns during progression of melanoma. Genes Chromosom. Cancer 2010, 49, 144–154.
44. Groth, A.; Kloss, S.; von Strandmann, E.P.; Koehl, U.; Koch, J. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J. Innate Immun. 2011, 3, 344–354.
45. Enderling, H.; Hlatky, L.; Hahnfeldt, P. Immunoediting: Evidence of the multifaceted role of the immune system in self-metastatic tumor growth. Theor. Biol. Med. Model. 2012, 9, 31.
46. Boss, J.M. Regulation of transcription of MHC class II genes. Curr. Opin. Immunol. 1997, 9, 107–113.
47. De Paus, R.A.; Kilic, S.S.; van Dissel, J.T.; van de Vosse, E. Effect of amino acid substitutions in the human IFN-γ2 on IFN-γ responsiveness. Genes Immun. 2011, 12, 136–144.
48. Gros, E.; Petzold, S.; Maintz, L.; Bieber, T.; Novak, N. Reduced IFN-γ receptor expression and attenuated IFN-γ response by dendritic cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2011, 128, 1015–1021.
49. Srisatjaluk, R.; Kotwal, G.J.; Hunt, L.A.; Justus, D.E. Modulation of γ interferon-induced major histocompatibility complex class II gene expression by porphyromonas gingivalis membrane vesicles. Infect. Immun. 2002, 70, 1185–1192.
50. Morris, A.C.; Beresford, G.W.; Mooney, M.R.; Boss, J.M. Kinetics of a γ interferon response: Expression and assembly of CIITA promoter IV and inhibition by methylation. Mol. Cell. Biol. 2002, 22, 4781–4791.
51. Truax, A.D.; Thakkar, M.; Greer, S.F. Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells. PLoS One 2012, 7, e36013.
52. Reinsbach, S.; Nazarov, P.V.; Philippidou, D.; Schmitt, M.; Wienecke-Baldacchino, A.; Muller, A.; Vallar, L.; Behrmann, I.; Kreis, S. Dynamic regulation of microRNA expression following interferon-γ-induced gene transcription. RNA Biol. 2012, 9, 978–989.
53. Rodriguez, T.; Mendez, R.; Del Campo, A.; Jimenez, P.; Aptsiauri, N.; Garrido, F.; Ruiz-Cabello, F. Distinct mechanisms of loss of IFN-γ mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 2007, 7, 34.
54. Serrano, A.; Tanzarella, S.; Lionello, I.; Mendez, R.; Traversari, C.; Ruiz-Cabello, F.; Garrido, F. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2’-deoxycytidine treatment. Int. J. Cancer 2001, 94, 243–251.
55. Respa, A.; Bukur, J.; Ferrone, S.; Pawelec, G.; Zhao, Y.; Wang, E.; Marincola, F.M.; Seliger, B. Association of IFN-γ signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin. Cancer Res. 2011, 17, 2668–2678.
56. Radosevich, M.; Song, Z.; Gorga, J.C.; Ksander, B.; Ono, S.J. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. Investig. Ophthalmol. Visual Sci. 2004, 45, 3185–3195.
57. Amalraj, J.; Cutler, S.J.; Ghazawi, I.; Boyle, G.M.; Ralph, S.J. Rest negatively and ISGF3 positively regulate the human STAT1 gene in melanoma. Mol. Cancer Ther. 2013, 12, 1288–1298.
58. Schoenherr, C.J.; Paquette, A.J.; Anderson, D.J. Identification of potential target genes for the neuron-restrictive silencer factor. Proc. Natl. Acad. Sci. USA 1996, 93, 9881–9886.
59. Cemazar, M.; Golzio, M.; Sersa, G.; Hojman, P.; Kranjc, S.; Mesojednik, S.; Rols, M.P.; Teissie, J. Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther. 2009, 16, 635–644.
60. Lin, F.; Shen, X.; Kichaev, G.; Mendoza, J.M.; Yang, M.; Armendi, P.; Yan, J.; Kobinger, G.P.; Bello, A.; Khan, A.S.; et al. Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum. Gene Ther. Methods 2012, 23, 157–168.
61. Rejman, J.; Tavernier, G.; Bavarsad, N.; Demeester, J.; de Smedt, S.C. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J. Control. Release 2010, 147, 385–391.
62. Tuxen, I.V.; Jonson, L.; Santoni-Rugiu, E.; Hasselby, J.P.; Nielsen, F.C.; Lassen, U. Personalized oncology: Genomic screening in phase 1. APMIS 2014, 122, 723–733.
63. Robertson, D.; Savage, K.; Reis-Filho, J.S.; Isacke, C.M. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol. 2008, 9, 13.